The short version
- Why people research itMitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
- What the evidence isMultiple randomized human trials, and the results are consistent in one direction and disappointing in another.
- What to watchPersistent nausea or loss of appetite.
How NR works
NAD+ precursor (a vitamin B3 form) — converts to NMN then NAD+ to support mitochondrial energy and sirtuin activity.
Nicotinamide riboside is the one NAD+ precursor with a dedicated enzyme, and that enzyme is the entire argument for it. Most routes into the NAD+ pool converge on NAMPT, the rate-limiting salvage enzyme that converts nicotinamide to nicotinamide mononucleotide.
NRK2 is the detail worth knowing, because it is where the tissue specificity comes from: NRK2 is concentrated in skeletal and cardiac muscle and is upregulated by muscle stress and damage. A precursor whose activating kinase is enriched in muscle and induced by injury is a plausible muscle-directed agent in a way that nicotinamide is not, and it is the mechanistic reason the muscle trials were the ones worth running.
- Oral
On the goal map: NAD+ & sirtuin signaling (Longevity & healthspan)
Research on NR7 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Human clinical evidence
Multiple randomized human trials, and the results are consistent in one direction and disappointing in another. That part is settled across trials.
What has not shown up is clinical benefit. Trials in healthy older adults, obese adults and heart failure have generally failed to demonstrate meaningful improvements in insulin sensitivity, mitochondrial function, muscle performance or exercise capacity. A few small studies report reductions in inflammatory markers.
This is the most important honest read on the whole NAD+ category: the biomarker moves, the outcome largely has not. That is a real finding, not a reason to dismiss the biology — it may mean the endpoint, population or duration was wrong. But it is where the evidence currently stands.
Correlative data
Reported experience is subtle — most users cannot tell, which is consistent with the trial results.
How the mechanism reads
Nicotinamide riboside is an NAD+ precursor. NAD+ declines with age and is the required cofactor for the sirtuins and PARPs — the enzymes doing DNA repair and metabolic regulation — so restoring it is a coherent target.
MechanisticNR enters the salvage pathway via NRK1/NRK2 kinases, a route NMN and nicotinamide do not use, which is the mechanistic argument for it over the alternatives.
MechanisticThe gap between raised NAD+ and absent benefit is the interesting question. Possibilities include tissue distribution (blood NAD+ may not reflect muscle or brain), that NAD+ was not the limiting factor in healthy people, or that the trials were too short. All are testable; none are resolved.
Mechanistic
Sources
- Trammell SA, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications 2016 · PMID 27721479
- Berven H, et al. Nature Communications 2023 · PMID 38016950
- Harrison DE, et al. 17-a-estradiol late in life extends lifespan in aging UM-HET3 male mice; nicotinamide riboside and three other drugs do not affect lifespan in either sex. Aging Cell 2021 · PMID 33788371
NR safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Active cancer or treatment: more NAD+ supports every cell, including tumor cells.
- Gout or high uric acid: faster NAD+ turnover ends in the purine and uric acid pathway.
- Pregnancy or breastfeeding: nicotinamide riboside at supplement exposure lacks safety data in either.
- Chronic liver disease: it adds to the NAD+ and nicotinamide load the liver must clear.
What’s expected
- Higher blood NAD+ levels, often with no felt effect.
- Mild nausea or stomach upset, usually settling in days.
- Less flushing than niacin, since it does not act on the niacin receptor.
- Some report a calmer energy lift.
Watch for
- Persistent nausea or loss of appetite.
- Yellow eyes or dark urine after weeks on a high NAD+ precursor load.
- A hot, swollen big toe or joint.
- Itching or hives.
Labs that tell you it’s working
- Uric Acid
- Homocysteine
- Comprehensive Metabolic Panel (CMP)
- Lipid Panel
NR converts to NMN then NAD+; excess nicotinamide is methylated by NNMT, so homocysteine, uric acid and liver labs show the load. PMID 29599478 PMID 38016950
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
NR FAQ4 common questions
- Is NR approved for human use?
- No. NR is a research compound.
- What is NR researched for?
- Mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
- Which labs show whether it's doing anything?
- Uric Acid; Homocysteine; Comprehensive Metabolic Panel; Lipid Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for NR: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



